1. Home
  2.  » 
  3. Expert Content
  4.  » 
  5. Cell Therapy
  6.  » Industrializing iPSC-Based Cell Therapies

Industrializing iPSC-Based Cell Therapies

Summary: Our iPSC banks utilize specialized reprogramming technology to transform commercial-use donor consented, clinically approved, cord blood collections into HLA-homozygous lines that are immune compatible with a wide population. The cell banks meet major regulatory agency requirements and the iPSC lines and corresponding donor tissue undergo extensive characterization.​

Click here to download the Fact Sheet